Literature DB >> 24383763

Using a single parameter to describe time-activity curves.

Cheuk S Kwok1, Paul H Frankel, George Lopatin, Lawrence E Williams.   

Abstract

Time-activity uptake curves [u(t) in % injected dose per gram of tissue] may be described by different--often complicated--functional forms. Because of the need to readily compare sequences of engineered radiopharmaceuticals, it is efficient to use mean residence time (MRT) as a one-parameter descriptor. In applying this computation to a sequence of five cognate anti-carcinoembryonic antigen (CEA) antibodies, it was found that the intact form had the longest MRT in the blood with the other four cognates having values less by approximately a factor of 10 or more. This difference probably follows from the lack of an intact Fc segment on the latter engineered molecules. MRT values for a sequence of six scFv-Fc engineered fragments demonstrated that the double mutant had the shortest blood residence time--30-fold less compared with the wild type. Whereas it is not possible to directly apply the MRT to nonbolus (tumor or organ) curves, a residence time (τ) may be assigned using the uptake function. Using τ, it was found that the intact (natural) form of the anti-CEA cognate set had the longest time at the tumor site in the human xenograft model in nude mice. The MRT and τ concept are proposed to also allow comparison of possible relative blood and tissue exposures, respectively, for cognate sets of unlabeled engineered antibodies used to treat malignancies although no data are yet available in the literature for this application.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24383763      PMCID: PMC3928828          DOI: 10.1089/cbr.2013.1568

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  9 in total

1.  Numerical selection of optimal tumor imaging agents with application to engineered antibodies.

Authors:  L E Williams; A M Wu; P J Yazaki; A Liu; A A Raubitschek; J E Shively; J Y Wong
Journal:  Cancer Biother Radiopharm       Date:  2001-02       Impact factor: 3.099

2.  On the theory of the indicator-dilution method for measurement of blood flow and volume.

Authors:  P MEIER; K L ZIERLER
Journal:  J Appl Physiol       Date:  1954-06       Impact factor: 3.531

3.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Authors:  Vania Kenanova; Tove Olafsen; Desiree M Crow; Gobalakrishnan Sundaresan; Murugesan Subbarayan; Nora H Carter; David N Ikle; Paul J Yazaki; Arion F Chatziioannou; Sanjiv S Gambhir; Lawrence E Williams; John E Shively; David Colcher; Andrew A Raubitschek; Anna M Wu
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

4.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Authors:  D G Maloney; A J Grillo-López; C A White; D Bodkin; R J Schilder; J A Neidhart; N Janakiraman; K A Foon; T M Liles; B K Dallaire; K Wey; I Royston; T Davis; R Levy
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

5.  Comparing time activity curves using the Akaike information criterion.

Authors:  Peter Kletting; Thomas Kull; Sven N Reske; Gerhard Glatting
Journal:  Phys Med Biol       Date:  2009-10-09       Impact factor: 3.609

6.  The derivation of the gamma-variate relationship for tracer dilution curves.

Authors:  R Davenport
Journal:  J Nucl Med       Date:  1983-10       Impact factor: 10.057

7.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

8.  Using smoothing spline anova to examine the relation of risk factors to the incidence and progression of diabetic retinopathy.

Authors:  Y Wang; G Wahba; C Gu; R Klein; B Klein
Journal:  Stat Med       Date:  1997-06-30       Impact factor: 2.373

9.  Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.

Authors:  M S Kaminski; J Estes; K R Zasadny; I R Francis; C W Ross; M Tuck; D Regan; S Fisher; J Gutierrez; S Kroll; R Stagg; G Tidmarsh; R L Wahl
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.